About human coagulati on factor
Blood-clotting factor replacement
Used for
- Prevention and treatment of bleeding in haemophilia A
- Bleeding prevention during surgery in haemophilia A
Usual adult dose
Dose is individualized by body weight, bleeding severity, and target clotting-factor level; given intravenously.
Usual dose in children
Individualized intravenous dosing, as for adults; used in children with haemophilia A.
Common side effects
- Allergic reactions, including rash or swelling
- Development of antibodies that reduce treatment effectiveness
- Headache or fever
- Injection-site reactions
Important warnings
- Use only for haemophilia A; it does not treat von Willebrand disease unless specifically indicated.
- Severe allergic reactions can occur, especially in people with factor VIII inhibitors.
- New or persistent bleeding may indicate inhibitors or inadequate treatment.
- Some products are made from human plasma; manufacturing reduces, but cannot eliminate, infection risk.
Pregnancy
Limited evidence; use when clearly needed to control or prevent bleeding, with specialist oversight.
Breastfeeding
Information is limited; treatment may be used when clinically needed, with specialist oversight.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.